Hansoh Pharma's dalmelitinib-aumolertinib improves progression-free survival in Phase 3 lung cancer trial

• Hansoh Pharma presented Phase 3 results for dalmelitinib combined with aumolertinib at the ESMO Congress on October 26, 2026.
• The combination significantly delayed disease progression versus platinum-based chemotherapy in advanced non-small cell lung cancer with EGFR mutations and MET amplification.
• The trial met its primary endpoint in patients whose disease progressed following EGFR inhibitor therapy.
• China's National Medical Products Administration accepted the combination's new drug application on February 27, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.